Under TRISENOX behandlingen havde 13 af de 52 patienter i APL- studierne et eller flere symptomer på APL- differentieringssyndrom karakteriseret ved feber, dyspnø, vægtforøgelse, pulmonære infiltrater og pleurale eller perikardiale effusioner med eller uden leukocytose (se Afsnit 4. 4).
During TRISENOX treatment, 13 of the 52 patients in the APL studies had one or more symptoms of APL differentiation syndrome, characterised by fever, dyspnoea, weight gain, pulmonary infiltrates and pleural or pericardial effusions, with or without leukocytosis (see Section 4.4).